Metrics as of 10/15/2026, 03:23 AM (Berlin time), refresh in progress.
Arcturus Therapeutics Holdings Stock
Arcturus Therapeutics Holdings Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Joseph E. Payne
- Employees
- 109
- Market cap
- $316 M
- IPO
- 22/05/2013
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine…
Arcturus Therapeutics Holdings stock: price history
1D
-7.6%
1W
-12.9%
1M
-27.3%
6M
+29.0%
YTD
+81.4%
1Y
-47.7%
2Y
-46.8%
5Y
-75.6%
10Y
-34.4%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~27% stronger price swings than usual
Ask the agents about Arcturus Therapeutics Holdings
Analyst assessment of Arcturus Therapeutics Holdings
PRICE TARGET LOW
US$20.00
CONSENSUS
US$30.50
MEDIAN
US$30.50
PRICE TARGET HIGH
US$41.00
0
STRONG BUY
12
BUY
5
HOLD
4
SELL
0
STRONG SELL
21
TOTAL · Buy
As of: 09/10/2026
Arcturus Therapeutics Holdings stock metrics
P/E
-3.34
P/B
1.84
EV/EBITDA
-1.79
RETURN ON EQUITY
-13.8%
NET MARGIN
-803.8%
DEBT/EQUITY
0.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
92.0%
FLOAT SHARES
26,153,203
AVG. DAILY VOLUME (30D)
809,570
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -7.6%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Arcturus Therapeutics Holdings stock
What does Arcturus Therapeutics Holdings do?
Arcturus Therapeutics Holdings Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Joseph E. Payne, the company employs around 109 people.
The IPO was on 22/05/2013; the stock trades on NASDAQ under the ticker ARCT.
What do analysts say about Arcturus Therapeutics Holdings stock?
21 analysts rate the stock, the consensus is Buy (as of 09/10/2026).
The average price target is US$30.50, ranging from US$20.00 to US$41.00, with a median of US$30.50.
This is an external assessment, not a statement by Market Jury.
When does Arcturus Therapeutics Holdings report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 27% stronger than usual.
Does Arcturus Therapeutics Holdings pay a dividend?
Yes. The last dividend was US$0.01 per share, ex-date 08/01/2013, paid on 15/01/2013.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Arcturus Therapeutics Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Arcturus Therapeutics Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Arcturus Therapeutics Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.